Side-Effects of Anti-Inflammatory Drugs 3, Softcover reprint of the original 1st ed. 1992
Inflammation and Drug Therapy Series, Vol. 5

The contents of this book represent papers which were presented at the Third International Meeting on "Side-Effects of Anti-Inflammatory and Analgesic Drugs" which was held under the auspices of the University of Verona, Institute of Pharmacology in Verona on 8-11 May 1991. This meeting was held in conjunction with the 13th European Workshop on Inflammation and although publications from this part of the meeting are not published here (they appear in Agents and Actions), we were fortunate in having a group of people interested in inflammation from varying backgrounds. The success of the third meeting followed previous meetings held in Cambridge and Verona respectively and continue a tradition which has now become well established. The meeting brought together physicians, scientists and those concerned with the production and use of anti-inflammatory drugs to a very stimulating conference to discuss basic issues affecting all aspects of side-effects of anti-inflammatory and analgesic drugs as well as their detection and treatment. The meeting was held in the Auditorium of Glaxo Italy and we are very grateful to that company for use of their facilities as well as to the University of Verona, Institute of Pharmacology, for valuable secretarial and administrative help. The success of the conference would not have been possible without valuable financial assistance of the companies listed separately (under Acknowledgements) as well as to the organizers of the 13th European Workshop on Inflammation who collaborated with us.

Section I: Epidemiology.- 1 The gastrointestinal toxicity of the non-steroidal anti-inflammatory drugs.- 2 The value of the case-control approach for the evaluation of the risk of upper gastrointestinal bleeding associated with the previous use of non-steroidal anti-inflammatory drugs.- 3 Liver toxicity of antipyretic drugs in conjunction with measles infections.- 4 Non-steroidal anti-inflammatory drugs and hypersensitivity reactions.- 5 What can a spontaneous reporting system teach about side-effects of anti-inflammatory drugs?.- 6 Adverse reactions to NSAIDs: consecutive evaluation of 30 000 patients in rheumatology.- Section II: Gastrointestinal Tract: Clinical Aspects.- 7 The evaluation of acute gastrointestinal toxicity of NSAIDs in phase I clinical trials: a critical appraisal.- 8 The ulcerogenic and anti-haemostatic effects of NSAIDs in the gut.- 9 What role does Helicobacter pylori infection play in NSAID-associated gastric inflammation?.- 10 Endoscopic evaluation of NSAID ulceration.- 11 Food antigen absorption in rheumatoid arthritis: effect of acetylsalicylic acid.- 12 Intestinal mucosal permeability in inflammatory rheumatic diseases.- 13 Comparison of effects on gastrointestinal blood loss and gastric mucosal appearance of piroxicam-?-cyclodextrin, piroxicam and placebo.- Section III: Gastrointestinal Tract: Prevention Of Adverse Effects.- 14 Mechanisms of gastrointestinal ulceration from non-steroidal anti-inflammatory drugs: a basis for use and development of protective agents.- 15 Novel strategies of gastric and duodenal mucosal protection against NSAID injury: role of protease inhibitors, muscle relaxants and growth factors.- 16 The role of misoprostol in preventing NSAID-induced damage to the gastrointestinal tract.- 17 Possible factors involved in the protective effects of interleukin-1 in aspirin- and indomethacin-induced gastric damage.- 18 Prevention and treatment of NSAID-gastroduodenal damage: the role of H2-receptor antagonists.- 19 Omeprazole in the prevention and therapy of gastroduodenal lesions on NSAID therapy.- 20 Sucralfate in the prevention of NSAID-induced gastric ulceration.- 21 Ketotifen - a novel approach to the prevention of damage in the gastrointestinal tract.- Section IV: Hepatotoxicity.- 22 The hepatotoxicity of non-steroidal anti-inflammatory drugs.- 23 Paracetamol (acetaminophen) bioactivation by liver microsomes - its role in hepatotoxicity.- 24 Increased liver toxicity of diclofenac by paracetamol: results and possible mechanisms.- 25 Effects of NSAIDs on liver microsomal mono-oxygenase system and products of oxidative metabolism of arachidonic acid.- 26 Hepatitis due to non-steroidal anti-inflammatory drugs (NSAIDs).- Section V: Nephrotoxicity.- 27 Current status of nephrotoxicity caused by non-steroidal anti-inflammatory drugs.- 28 Are oral prostaglandins effective in preventing nephrotoxicity from NSAIDs and cyclosporin?.- Section VI: Specific Issues Related To Side-Effects.- 29 Aspirin and Reye’s syndrome.- 30 Antirheumatic drug therapy in the elderly.- 31 NSAIDs and human cartilage metabolism.- 32 Non-steroidal anti-inflammatory drugs and the augmented lipoxygenase pathway: conceivable impact on joint conditions.- 33 Therapeutic potential of 5-lipoxygenase inhibitors: the discovery and development of MK-886, a novelmechanism leukotriene inhibitor.- 34 Mechanisms of rash formation and related skin conditions induced by non-steroidal anti-inflammatory drugs.- Section VII: Antirheumatic And Immunoregulatory Agents.- 35 Cyclosporin: clinical efficacy and toxicity in patients with rheumatoid arthritis.- 36 Risk factors and risk-benefit problems in the use of DMARDs.- 37 Gold toxicity: chemical, structural, biological and clinical experimental issues.- Section VIII: Extended Poster Presentations.- 38 A review of interaction studies between non-steroidal anti-inflammatory drugs and HTreceptor antagonists or prostaglandin analogues.- 39 Influence of different anti-inflammatory substances on ethanol- and indomethacin-induced gastrointestinal mucosal damage.- 40 The role of copper in preventing gastric damage by acetylsalicylic acid.- 41 Effect of NSAID therapy on plasma, whole blood cell (BC), and 24h urine zinc in patients with rheumatoid arthritis (RA).